ADAMTS13 (Q76LX8) variants and mutations
ADAMTS13 (also known as Q76LX8) is a human protein-coding gene encoding an a disintegrin and metalloproteinase with thrombospondin motifs 13 protein. It cleaves ultra-large von Willebrand factor multimers in the circulation, preventing excessive platelet adhesion in small vessels. Severe inherited deficiency or inhibitory autoantibodies cause thrombotic thrombocytopenic purpura, characterized by microvascular thrombosis, thrombocytopenia, and hemolytic anemia. This analysis covers 1,947 ADAMTS13 variants and mutations. Of these, 91% have computational variant effect predictions. Disease context includes congenital thrombotic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and Thrombocytopenia. Example ADAMTS13 variants include H2Y, H2R, and H2H.
Variant analysis overview
- Gene: ADAMTS13
- Protein: Q76LX8
- UniProt accession: Q76LX8
- Organism: Homo sapiens
- Variants analyzed: 1947
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 1,747 unspecified-consequence records; 86 missense variants; 79 synonymous variants; 14 frameshift variants; 6 stop-gained variants; 5 in-frame deletions; 2 splice-region variants; 1 in-frame insertions; 7 substitution
- Prediction scores: 1,767 variants have prediction scores (91% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: congenital thrombotic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, Thrombocytopenia, Abnormal bleeding, atypical hemolytic-uremic syndrome, hereditary disease, thrombotic disease, COVID-19, hepatocellular carcinoma, stroke disorder, Stroke, diabetes mellitus.
Protein structure and variant hotspots
- Protein features: 12 domains; 11 binding sites; 18 post-translational modification sites.
- Structural context: 1,315 variants have structural context.
- PTM context: 24 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable ADAMTS13 variants
Examples include H2Y, H2R, H2H, Q3K, Q3R, R4C, R4H, H5Q. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- H2Y (p.His2Tyr), ExAC rs782013900, TOPMed rs782013900, gnomAD rs782013900, REVEL 0.10, MetaLR 0.25
- H2R (p.His2Arg), gnomAD 9-133422448-A-G, REVEL 0.11, MetaLR 0.22
- H2H (p.His2His), rs782193624, gnomAD 9-133422449-C-T, CADD 0.46
- Q3K (p.Gln3Lys), ExAC rs782300973, gnomAD rs782300973, REVEL 0.08, MetaLR 0.35
- Q3R (p.Gln3Arg), Ensembl rs1840013960, MetaLR 0.26, MetaSVM -0.87
- R4C (p.Arg4Cys), rs782204201, ClinGen CA200878998, ClinVar RCV002610239, ExAC rs782204201, REVEL 0.14, MetaLR 0.39, Uncertain significance, not provided
- R4H (p.Arg4His), ExAC rs370406676, TOPMed rs370406676, gnomAD rs370406676, REVEL 0.17, MetaLR 0.28
- H5Q (p.His5Gln), 1000Genomes rs77985067, ExAC rs77985067, TOPMed rs77985067, gnomAD rs77985067, REVEL 0.07, MetaLR 0.35, Likely benign
- H5Y (p.His5Tyr), TOPMed rs1840014565, REVEL 0.13, MetaLR 0.32
- H5L (p.His5Leu), gnomAD 9-133422457-A-T, REVEL 0.13, MetaLR 0.33
- H5H (p.His5His), rs77985067, gnomAD 9-133422458-C-T, CADD 1.46
- P6R (p.Pro6Arg), ExAC rs782717483, gnomAD rs782717483, REVEL 0.17, MetaLR 0.42
- P6S (p.Pro6Ser), ESP rs375023076, ExAC rs375023076, gnomAD rs375023076, REVEL 0.20, MetaLR 0.42, Uncertain significance, Upshaw-Schulman syndrome; Inborn genetic diseases; not provided
- P6L (p.Pro6Leu), gnomAD 9-133422460-C-T, REVEL 0.10, MetaLR 0.37
- P6P (p.Pro6Pro), rs923235993, gnomAD 9-133422461-C-T, CADD 2.77
- R7G (p.Arg7Gly), 1000Genomes rs34024143, ESP rs34024143, ExAC rs34024143, TOPMed rs34024143, MetaLR 0.27, MetaSVM -0.88, Benign
- R7Q (p.Arg7Gln), rs782744929, ExAC rs782744929, TOPMed rs782744929, gnomAD rs782744929, REVEL 0.07, MetaLR 0.32, Uncertain significance, not provided
- R7W (p.Arg7Trp), rs34024143, 1000Genomes rs34024143, ESP rs34024143, ExAC rs34024143, REVEL 0.06, MetaLR 0.00, Benign/Likely benign, not provided; not specified
- R7P (p.Arg7Pro), gnomAD 9-133422457-A-AC, CADD 15.30
- R7R (p.Arg7Arg), rs34024143, gnomAD 9-133422462-C-A, CADD 0.33
- A8G (p.Ala8Gly), gnomAD 9-133422462-C-CG, CADD 7.68
- A8P (p.Ala8Pro), gnomAD 9-133422465-G-C, REVEL 0.24, MetaLR 0.42
- R9R (p.Arg9Arg), rs782112627, gnomAD 9-133422470-A-G, CADD 3.12
- C10Y (p.Cys10Tyr), TOPMed rs1291133178, gnomAD rs1291133178, REVEL 0.19, MetaLR 0.39
- C10C (p.Cys10Cys), rs1008512385, gnomAD 9-133422473-C-T, CADD 4.14
- P11S (p.Pro11Ser), gnomAD 9-133422474-C-T, REVEL 0.10, MetaLR 0.42
- P11L (p.Pro11Leu), gnomAD 9-133422475-C-T, REVEL 0.12, MetaLR 0.33
- P11P (p.Pro11Pro), gnomAD 9-133422476-T-A, CADD 1.07
- P12S (p.Pro12Ser), rs1446552024, ClinGen CA375706670, cosmic curated COSV10527, ClinVar RCV002614673, REVEL 0.09, MetaLR 0.32, Uncertain significance, not provided
- P12A (p.Pro12Ala), gnomAD 9-133422477-C-G, REVEL 0.04, MetaLR 0.33
- P12P (p.Pro12Pro), rs782511371, gnomAD 9-133422479-C-T, CADD 1.48
- L13P (p.Leu13Pro), rs782769020, gnomAD 9-133422476-T-TCC, CADD 9.71
- L13F (p.Leu13Phe), gnomAD 9-133422480-C-T, REVEL 0.08, MetaLR 0.39
- L13R (p.Leu13Arg), gnomAD 9-133422481-T-G, REVEL 0.34, MetaLR 0.50
- L13L (p.Leu13Leu), gnomAD 9-133422482-C-G, CADD 1.39
- C14F (p.Cys14Phe), ExAC rs782679501, TOPMed rs782679501, gnomAD rs782679501, REVEL 0.25, MetaLR 0.33, Uncertain significance
- C14S (p.Cys14Ser), ExAC rs782679501, TOPMed rs782679501, gnomAD rs782679501, REVEL 0.13, MetaLR 0.26, Uncertain significance, Upshaw-Schulman syndrome
- C14W (p.Cys14Trp), rs781957622, gnomAD 9-133422482-CTGTG, CADD 17.00
- A16D (p.Ala16Asp), gnomAD 9-133422490-C-A, REVEL 0.21, MetaLR 0.31
- A16A (p.Ala16Ala), rs782274726, gnomAD 9-133422491-C-T, CADD 2.67
- G17R (p.Gly17Arg), rs1554783636, ClinGen CA375706701, ClinVar RCV003827063, ClinVar RCV006307463, REVEL 0.46, MetaLR 0.67, Uncertain significance, Inborn genetic diseases; not provided
- G17* (p.Gly17Ter), gnomAD 9-133422492-G-T, CADD 34.00
- G17E (p.Gly17Glu), gnomAD 9-133422493-G-A, REVEL 0.30, MetaLR 0.63
- I18V (p.Ile18Val), ESP rs138886920, ExAC rs138886920, gnomAD rs138886920, MetaLR 0.28, MetaSVM -0.85
- I18S (p.Ile18Ser), gnomAD 9-133422496-T-G, REVEL 0.14, MetaLR 0.36
- L19F (p.Leu19Phe), rs782561010, ClinGen CA200879054, ClinVar RCV003861120, ClinVar RCV005040584, REVEL 0.29, MetaLR 0.67, Uncertain significance, Upshaw-Schulman syndrome; not provided
- L19V (p.Leu19Val), gnomAD 9-133422498-C-G, REVEL 0.20, MetaLR 0.49
- A20T (p.Ala20Thr), rs142293909, 1000Genomes rs142293909, ESP rs142293909, ExAC rs142293909, REVEL 0.04, MetaLR 0.26, Conflicting interpretations, not specified; Inborn genetic diseases; Upshaw-Schulman syndrome
- A20V (p.Ala20Val), NCI-TCGA TCGA novel, REVEL 0.07, MetaLR 0.36, Variant assessed as somatic; moderate impact.
- C21Y (p.Cys21Tyr), gnomAD 9-133422505-G-A, REVEL 0.18, MetaLR 0.35
- C21* (p.Cys21Ter), gnomAD 9-133422506-T-A, CADD 29.80
- C21C (p.Cys21Cys), gnomAD 9-133422506-T-C, CADD 3.05
- G22G (p.Gly22Gly), gnomAD 9-133422509-C-T, CADD 4.36
- F23F (p.Phe23Phe), rs1554783655, gnomAD 9-133422512-T-C, CADD 5.94
- L24L (p.Leu24Leu), rs782392800, gnomAD 9-133422515-C-T, CADD 5.72
- L25L (p.Leu25Leu), gnomAD 9-133422516-C-T, CADD 7.59
- C27R (p.Cys27Arg), gnomAD 9-133422522-T-C, REVEL 0.39, MetaLR 0.42
- W28* (p.Trp28Ter), rs2130769073, Ensembl rs2130769073, ClinGen CA375706775, ClinVar RCV002223117, CADD 35.00, Likely pathogenic
- W28C (p.Trp28Cys), gnomAD 9-133422527-G-C, REVEL 0.37, MetaLR 0.50
- G29* (p.Gly29Ter), rs1840019690, ClinGen CA375706780, ClinVar RCV002283959, AlphaMissense 0.21, MetaLR 0.65, Pathogenic
- G29A (p.Gly29Ala), TOPMed rs1387967134, gnomAD rs1387967134, REVEL 0.14, MetaLR 0.46
- G29E (p.Gly29Glu), TOPMed rs1387967134, gnomAD rs1387967134, REVEL 0.37, MetaLR 0.63
- G29R (p.Gly29Arg), Ensembl rs1840019690, NCI-TCGA Cosmic COSV1007, cosmic curated COSV10074, REVEL 0.44, AlphaMissense 0.21, Variant assessed as somatic; moderate impact.
- G29D (p.Gly29Asp), gnomAD 9-133422525-TG-T, CADD 23.30
- G29V (p.Gly29Val), gnomAD 9-133422529-G-T, REVEL 0.49, MetaLR 0.63
- G29G (p.Gly29Gly), rs781994399, gnomAD 9-133422530-A-G, CADD 0.69
- P30L (p.Pro30Leu), gnomAD rs1554783678, REVEL 0.08, MetaLR 0.19
- P30S (p.Pro30Ser), gnomAD rs1554783675, REVEL 0.06, MetaLR 0.31
- S31F (p.Ser31Phe), ExAC rs782296373, gnomAD rs782296373, REVEL 0.24, MetaLR 0.63, Uncertain significance, Upshaw-Schulman syndrome
- S31Y (p.Ser31Tyr), ExAC rs782296373, gnomAD rs782296373
- S31A (p.Ser31Ala), gnomAD 9-133422534-T-G, REVEL 0.16, MetaLR 0.39
- H32H (p.His32His), rs1840020699, gnomAD 9-133422539-T-C, CADD 1.28
- F33V (p.Phe33Val), Ensembl rs1564405781, REVEL 0.13, MetaLR 0.38
- F33S (p.Phe33Ser), rs782134844, gnomAD 9-133422540-TTC-T, CADD 17.10
- F33F (p.Phe33Phe), gnomAD 9-133422542-C-T, CADD 2.92
- Q34H (p.Gln34His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q34L (p.Gln34Leu), NCI-TCGA TCGA novel, MetaLR 0.41, MetaSVM -0.49, Variant assessed as somatic; moderate impact.
- Q35L (p.Gln35Leu), NCI-TCGA TCGA novel, MetaLR 0.39, MetaSVM -0.43, Variant assessed as somatic; moderate impact.
- Q35del (p.Gln35del), gnomAD 9-133422542-CCAG-, CADD 11.50
- Q35* (p.Gln35Ter), gnomAD 9-133422546-C-T, CADD 40.00
- Q35Q (p.Gln35Gln), gnomAD 9-133422548-G-A, CADD 23.20
- S36G (p.Ser36Gly), gnomAD rs1554784004, REVEL 0.10, MetaLR 0.37
- S36N (p.Ser36Asn), gnomAD rs1554784005, REVEL 0.16, MetaLR 0.35, Uncertain significance, Inborn genetic diseases
- C37Y (p.Cys37Tyr), gnomAD 9-133423105-G-A, REVEL 0.05, MetaLR 0.27
- C37F (p.Cys37Phe), gnomAD 9-133423105-G-T, REVEL 0.06, MetaLR 0.20
- L38F (p.Leu38Phe), NCI-TCGA TCGA novel, MetaLR 0.67, MetaSVM 0.24, Variant assessed as somatic; moderate impact.
- L38V (p.Leu38Val), gnomAD 9-133423107-C-G, REVEL 0.21, MetaLR 0.66
- A40G (p.Ala40Gly), gnomAD rs1554784008, REVEL 0.04, MetaLR 0.38
- A40S (p.Ala40Ser), gnomAD 9-133423113-G-T, REVEL 0.07, MetaLR 0.39
- A40A (p.Ala40Ala), rs1554784009, gnomAD 9-133423115-T-C, CADD 2.99
- L41W (p.Leu41Trp), Ensembl rs1588149754
- E42K (p.Glu42Lys), gnomAD 9-133423119-G-A, REVEL 0.20, MetaLR 0.50
- P43L (p.Pro43Leu), Ensembl rs999352582, REVEL 0.21, MetaLR 0.53
- P43S (p.Pro43Ser), gnomAD 9-133423122-C-T, REVEL 0.15, MetaLR 0.58
- Q44* (p.Gln44Ter), gnomAD rs1554784015, CADD 27.80
- Q44K (p.Gln44Lys), gnomAD rs1554784015, REVEL 0.05, MetaLR 0.23
- Q44L (p.Gln44Leu), gnomAD rs1554784018, REVEL 0.06, MetaLR 0.32
- Q44Q (p.Gln44Gln), gnomAD 9-133423127-G-A, CADD 2.85
- A45D (p.Ala45Asp), ExAC rs782570157, TOPMed rs782570157, gnomAD rs782570157, REVEL 0.12, MetaLR 0.28, Uncertain significance, not provided
- A45T (p.Ala45Thr), gnomAD 9-133423128-G-A, REVEL 0.11, MetaLR 0.30
- A45A (p.Ala45Ala), gnomAD 9-133423130-C-G, CADD 0.06
- V46L (p.Val46Leu), ExAC rs201522226, TOPMed rs201522226, gnomAD rs201522226, REVEL 0.09, MetaLR 0.32, Uncertain significance
- V46M (p.Val46Met), rs201522226, ClinGen CA200879426, cosmic curated COSV10743, ClinVar RCV001168076, REVEL 0.19, MetaLR 0.58, Uncertain significance, Inborn genetic diseases; not specified; Upshaw-Schulman syndrome
- V46V (p.Val46Val), rs369130757, gnomAD 9-133423133-G-T, CADD 0.69
- S48F (p.Ser48Phe), TOPMed rs1554784034, gnomAD rs1554784034
- S48Y (p.Ser48Tyr), TOPMed rs1554784034, gnomAD rs1554784034, REVEL 0.27, MetaLR 0.60
- S48A (p.Ser48Ala), gnomAD 9-133423137-T-G, REVEL 0.08, MetaLR 0.39
- S48S (p.Ser48Ser), gnomAD 9-133423139-T-C, CADD 0.44
- Y49C (p.Tyr49Cys), ESP rs373832736, TOPMed rs373832736, gnomAD rs373832736, REVEL 0.21, MetaLR 0.62, Uncertain significance, Inborn genetic diseases
- L50F (p.Leu50Phe), ExAC rs782217202, gnomAD rs782217202, REVEL 0.09, MetaLR 0.24
- L50W (p.Leu50Trp), TOPMed rs1252090544, gnomAD rs1252090544, REVEL 0.15, MetaLR 0.53
- L50L (p.Leu50Leu), gnomAD 9-133423143-T-C, CADD 2.71
- S51I (p.Ser51Ile), TOPMed rs1194058886, MetaLR 0.43, MetaSVM -0.21
- P52A (p.Pro52Ala), gnomAD 9-133423149-C-G, REVEL 0.10, MetaLR 0.29
- P52R (p.Pro52Arg), gnomAD 9-133423150-C-G, REVEL 0.05, MetaLR 0.29
- P52L (p.Pro52Leu), gnomAD 9-133423150-C-T, REVEL 0.05, MetaLR 0.31
- P52P (p.Pro52Pro), gnomAD 9-133423151-T-C, CADD 1.08
- G53A (p.Gly53Ala), gnomAD rs1554784062, MetaLR 0.25, MetaSVM -0.86
- G53D (p.Gly53Asp), rs1554784062, gnomAD rs1554784062, REVEL 0.03, MetaLR 0.26, Variant assessed as somatic; moderate impact.
- G53R (p.Gly53Arg), gnomAD 9-133423152-G-C, REVEL 0.11, MetaLR 0.30
- G53C (p.Gly53Cys), gnomAD 9-133423152-G-T, REVEL 0.20, MetaLR 0.41
- A54S (p.Ala54Ser), gnomAD 9-133423155-G-T, REVEL 0.09, MetaLR 0.32
- A54V (p.Ala54Val), gnomAD 9-133423156-C-T, REVEL 0.16, MetaLR 0.50
- P55S (p.Pro55Ser), gnomAD 9-133423158-C-T, REVEL 0.09, MetaLR 0.33
- P55H (p.Pro55His), gnomAD 9-133423159-C-A, REVEL 0.18, MetaLR 0.41
- L56L (p.Leu56Leu), rs782394264, gnomAD 9-133423163-A-G, CADD 0.22
- K57E (p.Lys57Glu), TOPMed rs1469680005, MetaLR 0.32, MetaSVM -0.76
- G58D (p.Gly58Asp), Ensembl rs1840135644
- G58V (p.Gly58Val), gnomAD 9-133424321-G-T, REVEL 0.07, MetaLR 0.40
- R59C (p.Arg59Cys), rs139735640, 1000Genomes rs139735640, ESP rs139735640, ExAC rs139735640, REVEL 0.18, MetaLR 0.34, Likely benign, not provided
- R59H (p.Arg59His), rs370929256, ESP rs370929256, ExAC rs370929256, TOPMed rs370929256, REVEL 0.06, MetaLR 0.19, Uncertain significance, not provided
- R59L (p.Arg59Leu), ESP rs370929256, ExAC rs370929256, TOPMed rs370929256, gnomAD rs370929256, REVEL 0.11, MetaLR 0.23, Uncertain significance
- R59R (p.Arg59Arg), gnomAD 9-133424325-C-T, CADD 0.22
- P60L (p.Pro60Leu), rs782677352, ClinGen CA200880107, ClinVar RCV002784366, ExAC rs782677352, REVEL 0.13, MetaLR 0.25, Uncertain significance, Inborn genetic diseases
- P60S (p.Pro60Ser), ESP rs370611753, TOPMed rs370611753, gnomAD rs370611753, REVEL 0.09, MetaLR 0.35, Uncertain significance, Inborn genetic diseases
- P60T (p.Pro60Thr), ESP rs370611753, TOPMed rs370611753, gnomAD rs370611753, REVEL 0.08, MetaLR 0.33, Uncertain significance, Upshaw-Schulman syndrome
- P60H (p.Pro60His), gnomAD 9-133424327-C-A, REVEL 0.11, MetaLR 0.38
- P61A (p.Pro61Ala), ExAC rs782680569, gnomAD rs782680569, REVEL 0.07, MetaLR 0.32
- P61R (p.Pro61Arg), TOPMed rs1554784541, gnomAD rs1554784541, REVEL 0.13, MetaLR 0.34, Uncertain significance, Upshaw-Schulman syndrome
- S62F (p.Ser62Phe), rs375370257, ESP rs375370257, ExAC rs375370257, TOPMed rs375370257, REVEL 0.08, MetaLR 0.36, Uncertain significance, not provided
- S62del (p.Ser62del), gnomAD 9-133424329-CCTT-, CADD 4.27
- S62Y (p.Ser62Tyr), gnomAD 9-133424333-C-A, REVEL 0.10, MetaLR 0.41
- P63R (p.Pro63Arg), gnomAD rs1554784553, REVEL 0.14, MetaLR 0.35
- P63S (p.Pro63Ser), gnomAD rs1554784549, REVEL 0.08, MetaLR 0.25
- P63P (p.Pro63Pro), rs1415996586, gnomAD 9-133424337-T-C, CADD 0.46
- G64S (p.Gly64Ser), gnomAD rs1840137624, REVEL 0.14, MetaLR 0.30
- G64D (p.Gly64Asp), gnomAD 9-133424339-G-A, REVEL 0.08, MetaLR 0.29
- G64G (p.Gly64Gly), gnomAD 9-133424340-C-T, CADD 5.91
- F65L (p.Phe65Leu), ExAC rs782453359, gnomAD rs782453359, REVEL 0.07, MetaLR 0.26
- Q66* (p.Gln66Ter), gnomAD rs1554784570
- Q66P (p.Gln66Pro), rs782456900, gnomAD 9-133424331-T-TTC, CADD 15.00
- Q68* (p.Gln68Ter), ExAC rs782576304, gnomAD rs782576304
- Q68R (p.Gln68Arg), TOPMed rs1196047412, gnomAD rs1196047412, REVEL 0.09, MetaLR 0.22, Uncertain significance, not provided
- R69K (p.Arg69Lys), rs2491058298, ClinGen CA375707062, ClinVar RCV002719639, REVEL 0.12, MetaLR 0.29, Uncertain significance, Inborn genetic diseases
- R69S (p.Arg69Ser), gnomAD 9-133424355-G-T, REVEL 0.08, MetaLR 0.26
- p.Gln70 Arg73del, rs781853881, gnomAD 9-133424343-CCAGA, CADD 17.10
- R71R (p.Arg71Arg), rs782220406, gnomAD 9-133424361-G-A, CADD 6.67
- Q72* (p.Gln72Ter), gnomAD rs1554784580, CADD 31.00
- p.Gln72 Arg73del, rs781853881, gnomAD 9-133424343-CCAGA, CADD 7.93
- Q72R (p.Gln72Arg), gnomAD 9-133424363-A-G, REVEL 0.06, MetaLR 0.26
- R73S (p.Arg73Ser), Ensembl rs1840139173
- p.Arg73 Arg74insGlnSer, rs1484827075, gnomAD 9-133424367-G-GCA, CADD 5.64
- R74G (p.Arg74Gly), TOPMed rs1255730642, gnomAD rs1255730642, MetaLR 0.43, MetaSVM -0.54
- R74Q (p.Arg74Gln), gnomAD rs1554784584, REVEL 0.07, MetaLR 0.36, Uncertain significance, Upshaw-Schulman syndrome
- R74W (p.Arg74Trp), rs1255730642, NCI-TCGA Cosmic COSV1007, cosmic curated COSV10074, TOPMed rs1255730642, REVEL 0.13, MetaLR 0.37, Variant assessed as somatic; moderate impact.
- R74P (p.Arg74Pro), gnomAD 9-133424369-G-C, REVEL 0.26, MetaLR 0.55
- R74R (p.Arg74Arg), gnomAD 9-133424370-G-A, CADD 8.51
- A75G (p.Ala75Gly), ESP rs142366230, ExAC rs142366230, TOPMed rs142366230, gnomAD rs142366230, REVEL 0.10, MetaLR 0.35
- A75S (p.Ala75Ser), gnomAD 9-133424371-G-T, REVEL 0.09, MetaLR 0.35
- A75A (p.Ala75Ala), rs143856697, gnomAD 9-133424373-T-C, CADD 6.13
- A76S (p.Ala76Ser), gnomAD rs1554784596, REVEL 0.05, MetaLR 0.32
- A76V (p.Ala76Val), ExAC rs782302107, gnomAD rs782302107, REVEL 0.06, MetaLR 0.27
- A76P (p.Ala76Pro), gnomAD 9-133424374-G-C, REVEL 0.20, MetaLR 0.46
- G77G (p.Gly77Gly), rs367627378, gnomAD 9-133424379-C-T, CADD 2.50
- G78C (p.Gly78Cys), 1000Genomes rs587712720, ExAC rs587712720, TOPMed rs587712720, gnomAD rs587712720, REVEL 0.29, MetaLR 0.46, Uncertain significance
- G78D (p.Gly78Asp), ExAC rs782188171, gnomAD rs782188171, cosmic curated COSV63023, REVEL 0.06, MetaLR 0.26
- G78S (p.Gly78Ser), 1000Genomes rs587712720, ExAC rs587712720, TOPMed rs587712720, gnomAD rs587712720, REVEL 0.05, MetaLR 0.25, Conflicting interpretations, Inborn genetic diseases; Upshaw-Schulman syndrome
- G78V (p.Gly78Val), ExAC rs782188171, gnomAD rs782188171, cosmic curated COSV10817, REVEL 0.08, MetaLR 0.31
- I79M (p.Ile79Met), rs281875297, Ensembl rs281875297, ClinGen CA220010, ClinVar RCV000059763, REVEL 0.18, MetaLR 0.49, not provided
- I79I (p.Ile79Ile), gnomAD 9-133424385-C-T, CADD 5.03
Public ADAMTS13 analysis runs
- ADAMTS13 analysis run — ADAMTS13 (1,947 variants) — completed 2026-08-21